A cost-effectiveness analysis of typhoid fever vaccines in US military personnel

PharmacoEconomics

Volumn 10, Issue 5, 1996, Pages 475-483

  Warren, Todd A ^a   Finder, Steven F ^b   Brier, Kenneth L ^b   Ries, Andrea J ^b   Weber, Mary P ^b   Miller, Melvin R ^b   Potyk, Roger P ^c   Reeves, C Stewart ^b   Moran, Errol L ^b   Tornow, John J ^d  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b US Dept Def Pharmacoeconomic Ctr   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d Foundation Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; TYPHOID VACCINE;

ARMY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENDEMIC DISEASE; FEVER; HEADACHE; HUMAN; IMMUNIZATION; INFLUENZA; INJECTION PAIN; MODEL; ORAL DRUG ADMINISTRATION; PARENTERAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHARMACOECONOMICS; PRIORITY JOURNAL; PRODUCTIVITY; TYPHOID FEVER; UNITED STATES; WORKING TIME;

EID: 10244222754     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610050-00005     Document Type: Article

References (35)

1. Levine MM. Typhoid fever vaccines. In: Plotkin SA, Mortimer EA. editors. Vaccines. Philadelphia: Saunders, 1994: 597-633
2. Bourne PG. Gaines S. An outbreak of typhoid fever in a special forces 'A' camp. Mil Med 1967; 132: 987-92
3. Long AP. Immunization. In: Coates JB. Huff CH. editors. United States Army Medical Services - preventative medicine in World War II. Vol 3. Personal health measures and immunization. Washington. DC: Government Printing Office, 1995: 276
4. Gentry LO, Hedlund KW, Wells RF. Bacterial diarrheal diseases. In: Ognihene AJ, Barrett O, editors. United States Army Medical Department - internal medicine in Vietnam. Vol 2. General medicine and infectious disease. Washington, DC: Government Printing Office, 1982: 363-5
5. United States Army Regulation 40-562. Washington, DC: Government Printing Office. 1989
6. United States Air Force Regulation 161-13. Washington. DC: Government Printing Office. 1990
7. United States Navy Bureau of Medicine and Surgery Notice 6230.3. Bethesda: United States Navy. 1993
8. Cieslak PR. Tauxe RV. Watson JC. Typhoid immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1994; 43 (RR-14): 1-7
9. Advice for travelers. Med Lett Drug Ther 1994; 36 (922): 41-4
10. Typhoid vaccine monograph. In: Olin BR, editor. Facts and comparisons. St Louis: Facts and Comparisons, Inc., 1990; 459
11. Typhim package insert. Connaught Laboratories, Inc., 1995
12. Sack DA, Freij L, Holmgren J. Prospects for public health benefits in developing countries from new vaccines against enteric infections. J Infect Dis 1991; 163: 503-6
13. Behrens RH, Roberts JA. Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers. BMJ 1994; 309: 918-22
14. Edelman R. Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986; 8: 329-49.
15. Typhoid vaccination: weighing the options (editorial). Lancet 1992; 340: 341-2
16. La Brooy JT. Tropical health: typhoid in 1993. Med J Aust 1993; 159: 598-601
17. Woodruff BA, Pavia AT, Blake PA. A new look at typhoid vaccination: information for the practicing physician. JAMA 1991; 265: 756-9
18. Rao N. Protecting travelers from typhoid. Infect Control Hosp Epidemiol 1991: 12: 168-72
19. Slater PE, Ostroy PR. Costin C. Typhoid vaccine: a double edged sword? Isr J Med Sci 1990; 26: 645
20. Typhoid vaccines: which one to choose? Drug Ther Bull 1993; 31 (3): 9-10
21. Levine MM, Ferreccio C, Black RE, et al. Chilean typhoid committee: progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11 Suppl. 3: S552-67
22. Levine MM. Modern vaccines: enteric fever. Lancet 1990; 335: 958-61
23. Acharya IL, Lowe CU, Thapa R. et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. N Engl J Med 1987; 317: 1101-4
24. Klugman KP, Gilbertson IT. Koornhof HJ, et al Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 11 (8569): 1165-9
25. Schwartz E. Schlim DR, Eaton M. et al. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch Intern Med 1990; 150: 349-51
26. Simanjuntak DH, Paleologo FP, Punjabi NH. et al. Oral immunization against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338: 1055-9
27. Ambrosch F, Fritzell B. Gregor J. et al. Combined vaccination against yellow fever and typhoid fever: a comparative trial. Vaccine 1994; 12: 625-8
28. Fritzell C, Rollin PE. Touir M. et al. Safety and immunogenicity of combined rabies and typhoid fever immunization. Vaccine 1992; 10: 299-300
29. Arnold WSG, Harcus AW. St Clair-Roherts J. et al. Experience with Vi typhoid capsular polysaccharide vaccine in the UK. J Infect 1992; 25: 63-6
30. Cumberland NS, St Clair-Roberts J, Arnold WSG. et al. Typhoid Vi: a less reactogenic vaccine. J Int Med Res 1992; 20: 247-53
31. Rahman S, Barr W, Hilton E. Use of oral typhoid vaccine strain Ty21a in a New York state travel immunization facility. Am J Trop Med Hyg 1993; 48: 823-6
32. Kaplan DT. Compliance with live, oral Ty21a typhoid vaccine [letter]. JAMA 1992; 267: 1074
33. Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992; 166: 1462-4
34. Brachman PS. Metchock B, Kozarsky PE. Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain. Clin Infect Dis 1992; 15: 1057-8
35. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100: 258-68